Small molecular therapies for rheumatoid arthritis: where do we stand?

Bibliography

• Goekoop-Ruiterman YP, de Vries-Bouwstra J, Allaart A, Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt Study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90
   PubMed Web of Science ®Google Scholar
• Verstappen SM, Jacobs JW, Van D, Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA). Ann Rheum Dis 2007; 66:34-45
   PubMedGoogle Scholar
• Breedveld FC, Weisman MH, Kavanaugh AF, The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37
   PubMed Web of Science ®Google Scholar
• Genovese MC, Mckay JD, Nasonov EL, Interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease –modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80
   PubMed Web of Science ®Google Scholar
• Klareskog L, van der Heidje D, de Jager J Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double blind randomized controlled trial. Lancet 2004;363:675-81
   PubMed Web of Science ®Google Scholar
• Kremer JM, Genant HK, Moreland LW, Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006;144:865-76
   PubMed Web of Science ®Google Scholar
• Weinblatt M, Bathon J, Kremer J, Safety and efficacy of etanercept beyond 10 years of therapy in north American patients with active rheumatoid arthritis. Arthritis Care Res 2010;63:373-82
   Web of Science ®Google Scholar
• Hetland M, Christensen J, Tarp U, Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry. Arthritis Rheum 2010;62:22-32
   PubMed Web of Science ®Google Scholar
• Hill RJ, Dabbagh K, Phippard D, Pamapimod, a novel p38 MAP kinase inhibitor: preclinical analysis of the efficacy and selectivity. J Pharmacol Exp Ther 2008. [Epub ahead of print]
   Web of Science ®Google Scholar
• Nishikawa M, Myoui A, Tomita T, Prevention of the onset and progression of collagen-induced arthritis in rats by the potent p38 mitogen-activated protein kinase inhibitor FR167653. Arthritis Rheum 2003;48:2670-81
   PubMed Web of Science ®Google Scholar
• Genovese MC, Cohen SB, Wofsy D, A randomized, double-blind, placebo controlled phase 2 study of an oral p38a MAPK inhibitor, SCIO-469, in patients with active rheumatoid arthritis. J Rheumatol 2011;38(5):846-54
   PubMed Web of Science ®Google Scholar
• Cohen SB, Cheng TT, Chindalore V, Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. Arthritis Rheum 2009;60:1232-41
   PubMedGoogle Scholar
• Genovese M. Inhibition of p38: has the fat lady sung? Arthritis Rheum 2009;60:317-20
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Janus kinases in immune signaling. Immunol Rev 2009;228:273-87
   PubMed Web of Science ®Google Scholar
• Pesu M, Candotti F, Husa M, Jak3, severe combined immunodeficiency, and a new class of immunosuppressive drugs. Immunol Rev 2005;203:127-42
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Laurence A, O'Shea JJ. Selectivity and therapeutic inhibition of kinases: to be or not to be? Nat Immunol 2009;10:356-60
   PubMed Web of Science ®Google Scholar
• Levine RL, Steensma D, Dewald G, Activating mutation in the tyrosine kinase Jak2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97
   PubMed Web of Science ®Google Scholar
• Druker BJ, Guilhot F, O'Brien S, Five year followup of patients receiving imitinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17
   PubMed Web of Science ®Google Scholar
• Tokumasa N, Suto A, Kagami S, Expression of Tyk2 in dendritic cells is required for IL-12, IL-23 and IFN-gamma production and the induction of Th1 cell differentiation. Blood 2007;110:53-560
   Google Scholar
• Changelian PS, Moshinsky D, Kuhn CF, The Specificity of Jak3 kinase inhibitors. Blood 2007;111:2155-7
   PubMed Web of Science ®Google Scholar
• Ghoreschi K, Jesson M, Li X, Modulation of innate and adaptive immunity responses by tofacitinib. J Immunol 2011; 186:4234-43
   PubMed Web of Science ®Google Scholar
• Kremer JM, Bloom BJ, Breedveld FC, The safety and efficacy of a Jak inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo controlled phase 11a trial of three dosage levels of CP-690,550 versus placebo. Arthritis Rheum 2009;60:1895-905
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Genovese M, Gruben D, Safety and efficacy after 24 week dosing of the inhibitor CP-690,550 as monotherapy in patients with active rheumatoid arthritis. Arthritis Rheum 2009;60
   Google Scholar
• Kremer JM, Cohen S, Wilkinson B, Safety and Efficacy after 24 week dosing of the oral JAK inhibitor CP-690,550, an orally active janus kinase inhibitor in combination with methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2009;60
   Google Scholar
• Kremer J, G-Li Z, Hall S, Tofacitinib (CP-690,550), an oral Jak inhibitor, in combination with traditional DMARDs: phase 3 study in patients with active rheumatoid arthritis with inadequate response to DMARDs. Ann Rheum Dis 2011;70:Suppl 3
   Google Scholar
• Williams W, Schefle P, Shi J, A Randomized placebo controlled trial of INCB018424, a selective janus kinase 1&2 inhibitor in rheumatoid arthritis. Arthritis Rheum 2008;58:S431
   Web of Science ®Google Scholar
• Hammaker D, Firestein GS. “Go Upstream, young man” lessons learnt form the p38 saga. Ann Rheum Dis 2010;69(Suppl 1):77-82
   PubMed Web of Science ®Google Scholar
• Cha HS, Boyle DS, Inoue T, A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes. J Pharmacol Exp Ther 2006;317:571-8
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Treatment of rheumatoid Arthritis with a Syk inhibitor. Arthritis Rheum 2008;58:3309-18
   PubMed Web of Science ®Google Scholar
• Weinblatt ME, Kavanaugh A, Genovese MC, An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. N Engl J Med 2010;363:1303-12
   PubMed Web of Science ®Google Scholar
• Genovese MC, Kavanaugh A, Weinblatt ME, An oral Syk kinase in the treatment of rheumatoid arthritis-A three-month randomized, placebo controlled, phase 11 study in Patients with active rheumatoid arthritis that did not respond to biologic agents. Arthritis Rheum 2011;63:337-45
   PubMed Web of Science ®Google Scholar
• Lai W, Irwan AW, Goh HH, Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. J Immunol 2008;181:8010-17
   PubMed Web of Science ®Google Scholar
• Fleischmann R, Poiley J, Stoilov R, The oral S1P lyase inhibitor LX3305 (A.K.A. LX2931) demonstrates favorable safety and potential clinical benefit at 12-weeks in a phase 2 proof-of-concept trial in patients with active rheumatoid arthritis on stable methotrexate therapy. Ann Rheum Dis 2011;70(Suppl3):87
   Google Scholar
• Campbell IK, Rich MJ, Bischof RJ, The colony-stimulating factors and collagen-induced arthritis: exacerbation of disease by M-CSF and G-CSF and requirement for endogenous M-CSF. J Leucocyte Biol 2000;68:144-50
   PubMed Web of Science ®Google Scholar
• Kitaura H, Zhou P, Ju Kim H, M-CSF mediated TNF-induced inflammatory osteolysis. J Clin Invest 2005;115:3418-27
   PubMed Web of Science ®Google Scholar
• Semmler J, Wachtel H, Endres S. The specific type IV phosphodiesterase inhibitor rilopram suppresses tumor necrosis factor-alpha production by human mononuclear cells. Int J Immunopharmacol 1993;15:409-13
   PubMed Web of Science ®Google Scholar
• Schett G, Wollenhaupt J, Papp K, Apremilast is active in the treatment of rheumatoid arthritis [abstract 1258]. Arthritis Rheum 2009;60:S10
   Google Scholar
• McCann F, Palfreeman A, Andrews M, Apremilast, a novel PDE4 inhibitor, inhibits spontaneous production of tumor necrosis factor-alpha from human rheumatoid synovial cells and ameliorates experimental arthritis. Arthritis Res Ther 2010;12:R107-18
   PubMed Web of Science ®Google Scholar